Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012. The purpose of our study was to compare rates of VTE and major bleeding between rivaroxaban and our previous protocol of enoxaparin after THA/TKA. A retrospective cohort study was performed including 2406 consecutive patients at our institution between 1/1/11 and 9/30/13. Patients who did not have unilateral primary THA/TKA or who received other anticoagulants were excluded. Of the 1762 patients included, 1113 patients (63.2%) received enoxaparin and 649 patients (36.8%) received rivaroxaban. This study found no demonstrable differences between these two anticoagulants in rates of VTE, infection, reoperation, transfusion, or major bleeding. Therapeutic, Retrospective comparative study, Level III.
Henry Ford Health System Department of Orthopaedic Surgery, Detroit, Michigan. Electronic address: michael.charters@gmail.com.
Michael A
MA
Charters
Henry Ford Health System Department of Orthopaedic Surgery, Detroit, Michigan.
Nicholas B
NB
Frisch
Henry Ford Health System Department of Orthopaedic Surgery, Detroit, Michigan.
Nolan M
NM
Wessell
Wayne State University School of Medicine, Detroit, Michigan.
Christopher
C
Dobson
Henry Ford Health System Department of Orthopaedic Surgery, Detroit, Michigan.
Clifford M
CM
Les
Henry Ford Health System Department of Orthopaedic Surgery, Detroit, Michigan.
Craig D
CD
Silverton
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D017984:Enoxaparin / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors / Q000737:chemistry; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000069552:Rivaroxaban / Q000627:therapeutic use*; D054556:Venous Thromboembolism / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D000069552:Rivaroxaban
DVT; PE; VTE; enoxaparin; factor Xa inhibitor; rivaroxaban